Medrx Co., Ltd. (JP:4586)

:4586

4586

Medrx Co., Ltd.

RESEARCH TOOLSreports

Want to see JP:4586 full AI Analyst Report?

Medrx Co., Ltd. (4586) Price & Analysis

0 Followers

4586 Stock Chart & Stats

¥113.00

¥2.00(2.50%)

At close: Jan 08 4:00 PM EST

¥113.00

¥2.00(2.50%)

Day’s Range― - ―

52-Week Range¥56.00 - ¥225.00

Previous CloseN/A

Volume596.00K

Average Volume (3M)2.57M

Market Cap

¥3.38B

Enterprise Value¥2.40B

Total Cash (Recent Filing)¥1.67B

Total Debt (Recent Filing)¥0.00

Price to Earnings (P/E)―

Beta1.39

Next Earnings

Aug 07, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-28.53

Shares Outstanding59,365,100

10 Day Avg. Volume1,116,360

30 Day Avg. Volume2,574,156

Financial Highlights & Ratios

PEG Ratio1.03

Price to Book (P/B)2.83

Price to Sales (P/S)45.31

P/FCF Ratio-5.98

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

High Gross Margins & Revenue ReboundSustained gross margins near 85–90% indicate strong product economics and pricing power typical in specialty drug manufacturing. Combined with a 2025 revenue rebound, this creates a structural pathway to profitability if operating expenses and scale efficiencies are controlled over the next several quarters.

Very Low Leverage / No Reported DebtA debt-free balance sheet materially reduces fixed financial obligations and interest risk, preserving flexibility to fund operations, R&D or partnerships via equity or cash reserves. This structural strength supports survival through cash burn periods without debt service pressure.

Lean Operating StructureA very small workforce implies low fixed operating overhead and potential capital efficiency in R&D and commercialization. Structurally, lean teams can redeploy capital faster, limit escalation of SG&A, and pivot product strategy without large legacy payroll burdens that impede margin improvement.

Bears Say

Persistent Negative Operating And Free Cash FlowConsistent negative operating and free cash flow forces reliance on external financing or equity dilution to sustain operations. Over months this erodes liquidity buffers, constrains investment in commercial scale-up, and increases execution risk if capital markets tighten or fundraising terms worsen.

Deep And Worsening Net LossesVery large and deteriorating net losses indicate costs far outstrip revenue and will erode shareholder equity if sustained. Structurally, this reduces reinvestment capacity, deters strategic partners, and raises the probability of dilutive financing or asset sale to cover ongoing deficits.

Volatile Revenue TrendHigh revenue volatility undermines predictability of cash flows and the ability to scale fixed-cost leverage. For a specialty drug maker, uneven sales make planning manufacturing, regulatory spend and commercial investment difficult, slowing durable margin expansion and extending the timeline to sustainable profitability.

4586 FAQ

What was Medrx Co., Ltd.’s price range in the past 12 months?

Medrx Co., Ltd. lowest stock price was ¥56.00 and its highest was ¥225.00 in the past 12 months.

What is Medrx Co., Ltd.’s market cap?

Medrx Co., Ltd.’s market cap is ¥3.38B.

When is Medrx Co., Ltd.’s upcoming earnings report date?

Medrx Co., Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 61 days.

How were Medrx Co., Ltd.’s earnings last quarter?

Medrx Co., Ltd. released its earnings results on May 15, 2026. The company reported -¥4.02 earnings per share for the quarter, missing the consensus estimate of N/A by -¥4.02.

Is Medrx Co., Ltd. overvalued?

According to Wall Street analysts Medrx Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Medrx Co., Ltd. pay dividends?

Medrx Co., Ltd. does not currently pay dividends.

What is Medrx Co., Ltd.’s EPS estimate?

Medrx Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Medrx Co., Ltd. have?

Medrx Co., Ltd. has 59,365,100 shares outstanding.

What happened to Medrx Co., Ltd.’s price movement after its last earnings report?

Medrx Co., Ltd. reported an EPS of -¥4.02 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.063%.

Which hedge fund is a major shareholder of Medrx Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4586

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Medrx Co., Ltd.

MedRx Co., Ltd, a pharmaceutical formulation development company, provides pharmaceutical drugs based on the transdermal absorption system in Japan. The company develops medicines based on Ionic liquid transdermal system (ILTS) and Nano-sized Colloid Transdermal System (NCTS); and researches and develops painless transdermal administration system for vaccines, nucleic acid medicines, protein medicines, etc. Its products pipeline includes MRX-4TZT, which is in phase I clinical trials for the treatment of spastic paralysis; MRX-9FLT that is in phase I clinical trials to treat chronic, cancer, and severe pain; and MRX-7MLL and MRX-6LDT that is in pre-clinical trials to treat Alzheimer's disease and chronic pain, as well as MRX-5LBT that has completed the clinical trials for the treatment of postherpetic nerve pain. MedRx Co., Ltd was incorporated in 2002 and is headquartered in Higashikagawa, Japan.